Results 111 to 120 of about 684,663 (243)

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source

Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes

, 2019
Aim: To determine if silencing PD-1 on tumor-infiltrating lymphocytes (TILs) and its ligand-1 (PD-L1) on cancer cells will enhance the cytotoxicity of TILs.
Chen, Chen, Xu, Zhi Ping, Gu, Wenyi, Li, Jiang, Wu, Yanheng   +4 more
core   +1 more source

Summary results for patients in the PD-L1-high model.

, 2020
Summary results for patients in the PD-L1-high model.
Juan Wisnivesky (8374794), Adelle M. Paquette (8374791), Lauren Palazzo (4836135), Tina R. Watson (7067750), Keith Sigel (8313861), Chung Yin Kong (8374797), Steven D. Criss (3821332)   +6 more
core   +1 more source

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell & Bioscience, 2018
Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain tumors and host immune cells, and its expression can be induced or maintained
Fei Tang, Pan Zheng
doaj   +1 more source

eQTL Meta‐Analysis Reveals Conserved and Population‐Specific Regulatory Variation Underlying Nutritional Trait Evolution and Domestication in Tomato

Advanced Science, EarlyView.
A comprehensive meta‐analysis of expression quantitative trait loci (eQTLs) across five diverse tomato populations reveals a high‐resolution atlas of transcriptional regulation and uncovers conserved and population‐specific regulatory architectures underlying fruit nutritional quality traits, including flavonoids, sugars, organic acids, carotenoids ...
Jiantao Zhao, Xin Wang, Jing Zhang, Ryan McQuinn, Je Min Lee, Itay Gonda, Ari Feder, Yimin Xu, Baike Wang, Qinghui Yu, Denise M. Tieman, Sanwen Huang, Harry Klee, James J. Giovannoni, Zhangjun Fei   +14 more
wiley   +1 more source

Icariin Enhances the Enzymatic Activity of N‐acetylgalactosaminidase to Augment Akkermansia Abundance in Gut Microbiota for Improved PD‐1 Blockade Efficacy in Tumor Suppression

Advanced Science, EarlyView.
Icariin promoted the growth of Akk by enhancing the activity of N‐acetylgalactosaminidase (Amuc_0920), which enhanced mucin utilization and provided a favorable nutrient environment for bacterial growth. This icariin‐mediated enrichment of Akk further reshaped the tumor microenvironment and promoted CD8+ T cell infiltration, ultimately synergizing with
Shuangying Qiao, Liu Yang, Haibang Hao, Qiuxia Ding, Feng Ding, Zheng Chen, Jinfang Zhang, Yun He, Meng Li, Jun Xu, Chao Wang, Aiping Lu, Fangfei Li   +12 more
wiley   +1 more source

Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction

Cell Reports
Summary: The CTLA-4 and PD-1 checkpoints control immune responses and are key targets in immunotherapy. Both pathways are connected via a cis interaction between CD80 and PD-L1, the ligands for CTLA-4 and PD-1, respectively. This cis interaction prevents
Maximillian A. Robinson, Alan Kennedy, Carolina T. Orozco, Hung-Chang Chen, Erin Waters, Dalisay Giovacchini, Kay Yeung, Lily Filer, Claudia Hinze, Christopher Lloyd, Simon J. Dovedi, David M. Sansom   +11 more
doaj   +1 more source

PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups.

, 2021
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and immunoarchitectural features by automated morphometric analysis using multiplex ...
Pahud de Mortanges, Aurélie, Gloor, Beat, Karamitopoulou, Eva, Tinguely, Marianne, Andreou, Andreas, Perren, Aurel   +5 more
core   +1 more source

O‐GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer

Advanced Science, EarlyView.
This article unveils a critical mechanism of immune evasion in bladder cancer, which the O‐GlcNAc modification of TAP1 disrupts antigen presentation. This modification triggers HLA‐A degradation, shielding tumor cells from CD8+ T cell attack. The findings highlight targeting this pathway as a promising therapeutic avenue to sensitize tumors to ...
Jinpeng Wu, Xueting Ren, Zhen Zhai, Lu Wang, Liang Liang, Zengqi Tan, Jiazhen Zhao, Yuxuan Han, Yuhan Li, Feng Guan, Xiang Li   +10 more
wiley   +1 more source